Evonik Industries Ag · XETR:EVK
Evonik Industries — Q3 2026 Earnings Presentation
34 slides from Evonik Industries's earnings presentation, Nov 3, 2026
Slide 1: Evonik Company Presentation Q3 2026
Evonik Company Presentation Q3 2026 1 November 2026 | Evonik 2026 Company Presentation
Slide 2: Agenda
Agenda 1 Evonik at a glance 1 Evonik at a glance 2 Our path to ~11% ROCE by 2029 2 Our path to ~11% ROCE by 2029 3 Financial Performance Q3 2026 3 Financial Performance Q3 2026 2 November 2026 | Evonik 2026 Company Presentation
Slide 3: Evonik at a glance
Evonik at a glance €14.1 bn Custom Solutions Sales Innovation-driven businesses with €1.9 bn (13.3%) tailored and Adj. EBITDA (margin) science-based LEADING solutions €695 m (37%) BEYOND Free Cash Flow (conversion) CHEMISTRY Advanced Technologies 6.1% Efficiency-driven businesses with a high ROCE le
Slide 4: We deliver products and solutions that improve life, every day
We deliver products and solutions that improve life, every day Nutrition Electronics Pharma & Health Care Every second Every second, Every third Consumer microchip over 1000 chicken in the US is acid-reflux patients is fed with produced using feel better thanks methionine hydrogen to Evonik tablet f
Slide 5: Our product portfolio: End market split and product examples
Our product portfolio: End market split and product examples 0-4% 5-10% 10-15% 15-20% Other Industries Automotive, Transportation & Machinery ▪ Gas-separation Membranes ▪ Coating additives for topcoats / under body coating ▪ Silanes and high-purity H2O2 for electronics industry / ▪ Silica / Silanes
Slide 6: Why invest in Evonik?
Why invest in Evonik? EVONIK – LEADING BEYOND CHEMISTRY Tailored solutions and industrial excellence Leading Portfolio Sustainable Innovation Regional Balance Team Excellence Shareholder Return We are best positioned We are banking on We are striving for a We are engaged as a = We are committed to f
Slide 7: Agenda
Agenda 1 Evonik at a glance 1 Evonik at a glance 2 Our path to ~11% ROCE by 2029 2 Our path to ~11% ROCE by 2029 3 Financial Performance Q3 2026 3 Financial Performance Q3 2026 7 November 2026 | Evonik 2026 Company Presentation
Slide 8: Our path to ~11% ROCE by 2029 is underpinned by tangible strategic levers
Our path to ~11% ROCE by 2029 is underpinned by tangible strategic levers – at the same time driving up earnings and reducing capital employed Adj. EBIT 1 2 Ongoing strong emphasis GROWTH EFFICIENCY 3 PORTFOLIO CHANGE ~11% ROCE1 by 2029 Employed Capital Enhanced focus CAPEX NWC 4 5 1. Adj. EBIT / Ca
Slide 9: Growth: Sustainable innovation as long-term sales and earnings driver
Growth: 1 Sustainable innovation as long-term sales and earnings driver Evonik Innovation Growth Areas Expanding into fast growing end markets1 Biosurfactants ▪ From cleaning to ~20% €1.5 bn additional sales by 2032 at >20% margin cosmetics and industrial applications Lightweight materials ▪ Foams u
Slide 10: Growth: Investing into Custom Solutions
Growth: Investing into Custom Solutions 1 Evonik launches new projects in additives and biotechnology Biotechnology expansion project Siloxane capacity expansion New GMP2 facility for for drug substance contract for PU1 foam and coating additives lipid-based drug delivery systems manufacturing Accel
Slide 11: Efficiency: Organization tailored to our businesses needs
Efficiency: Organization tailored to our businesses needs 2 leading to more agility and tight cost control Evonik Tailor Made Phase 1 Phase 2 2024-2026 2027-2029 Organization in 2029 ▪ Empowered businesses Reorganization and faster decision-making “Evonik Tailor Made” Holistic ▪ Reduced complexity a
Slide 12: Efficiency: ETM phase two integrates decisive business optimization measures
Efficiency: 2 ETM phase two integrates decisive business optimization measures Improved raw material Asset network Operational excellence Portfolio focus shift sourcing optimization ▪ Review business models ▪ Backward integration in ▪ Site consolidation: ▪ Continuous portfolio according to market Mo
Slide 13: Portfolio change: Focusing on our strong core by executing major divestments
Portfolio change: 3 Focusing on our strong core by executing major divestments Evonik core Divestments Advanced Technologies Custom Solutions Efficiency-driven Innovation-driven Oxeno divestment firmly Best owner process for businesses with a high businesses with tailored on track, aiming for SYNEQT
Slide 14: Capex: Sustainable reduction in capital intensity
Capex: Sustainable reduction in capital intensity 4 thanks to a structural shift in our investment approach Capex vs. adj. D&A (in € m) Structural shift in investment approach enabling sustainably lower capex Bar chart: Capex | Line chart: Adj. D&A 1,140 1,135 1,038 1,013 From… To… ▪ Add
Slide 15: Net working capital: AI-enabled tighter control reducing capital employed
Net working capital: 5 AI-enabled tighter control reducing capital employed Today: ~18% NWC to sales ratio with significant optimization efforts towards year-end Optimization of inventory Optimization of accounts receivables/ accounts payables ▪ AI-enhanced forecasting (IBP) → Better demand planning
Slide 16: We execute on our strategy with full force
We execute on our strategy with full force – building a focused, more agile company with ~11% ROCE by 2029 We drive We tightly manage We optimize ROCE earnings growth our capital base our portfolio ~11% Sustainably >8% Growth investments Oxeno & SYNEQT lower capex 6.1% Tight NWC Efficiency gains Sma
Slide 17: Agenda
Agenda 1 Evonik at a glance 1 Evonik at a glance 2 Our path to ~11% ROCE by 2029 2 Our path to ~11% ROCE by 2029 3 Financial Performance Q3 2026 3 Financial Performance Q3 2026 17 November 2026 | Evonik 2026 Company Presentation
Slide 18: Strong financial performance with Q3 delivered as guided
Strong financial performance with Q3 delivered as guided … … coupled with disciplined strategy execution Continued strong operating performance €629 m (+40% yoy) 16.4% (+3.2pp yoy) in Q3 2026 as guided adj. EBITDA in Q3 adj. EBITDA margin in Q3 Delivering standout cash conversion €601 m (doubled yoy
Slide 19: Q3 2026 results overview
Q3 2026 results overview Sales (in € m) Sales (yoy) Adj. EBITDA (in € m) Volume Price +2% +10% 3,825 FX Other 629 (Q3 2025: 3,391) (Q3 2025: 448) +/-0% +1% Capex1 (in € m) Free Cash Flow (in € m) Adj. EPS (in €) 193 369 0.71 (Q3 2025: 181) (Q3 2025: 300) (Q3 2025: 0.27) 1. Cash outflows for investme
Slide 20: Continued strong operating performance in Q3: Adj. EBITDA of €629 m
Continued strong operating performance in Q3: Adj. EBITDA of €629 m (+40% yoy) and 16.4% margin (+3.2pp) Adj. EBITDA (in € m) / Margin (in %) Drivers of Q3 performance ▪ Solid performance in Custom Solutions (+7% yoy) +40% ▪ Exceptional quarter for Advanced Technologies (+87% yoy) 630 629 −
Slide 21: Free Cash Flow after nine months more than doubled
Free Cash Flow after nine months more than doubled vs. last year’s level – well on track for 40% cash conversion rate in FY 2026 Free Cash Flow (in € m) Supporting factors for strong FCF Q3 9M ▪ FCF after nine months >€300 m ahead of last year +317 resulting in significant deleveraging 601 ▪ S
Slide 22: Confident to achieve upper half of guidance range for FY 2026
Confident to achieve upper half of guidance range for FY 2026 of adj. EBITDA of €2.0 - 2.2 bn Adj. EBITDA (in € bn) Drivers for Q4 adj. EBITDA upper half of ▪ FY guidance (“upper half of range”) €2.0 - 2.2 bn implies solid yoy earnings growth also in Q4 1.874 1.9 ▪ Good finish to a very strong year
Slide 23: Confident to achieve a cash conversion rate of 40%
Confident to achieve a cash conversion rate of 40% – implying FCF of ~€850 m for FY 2026 Free Cash Flow (in € m) / Conversion rate1 (in %) Cash generation aligned w/ capital allocation priorities CCR1 37% ~40% Disciplined investments into growth: Tight capex budget of ~€750 m in 2026 ~ €850 m suffic
Slide 24: Additional indications for FY 2026
Additional indications for FY 2026 Sales Around €15 bn (unchanged; 2025: €14.1 bn) ROCE Considerably above prior-year level: >8% (previously: slightly above prior-year level; 2025: 6.1%) Capex1 Around €750 m (unchanged; 2025: €748 m) EUR/USD sensitivity2 +/-1 USD cent = -/+ ~€5 m adj. EBITDA (FY bas
Slide 25: Custom Solutions
Custom Solutions Q3 26 vs. Q3 25 Volume Price FX Other Additives (adj. EBITDA up yoy) +/-0% +5% +/-0% -1% ▪ Solid sales (+6%) and earnings growth vs. prior year, Sales mainly driven by stronger oil and coating additives (in € m) +4% as well as catalyst businesses Additives 1,422 1,394 ▪ Comp
Slide 26: Advanced Technologies
Advanced Technologies Q3 26 vs. Q3 25 Inorganics (adj. EBITDA up yoy) Volume Price FX Other Sales ▪ Silica benefits from network optimization; positive volume +4% +14% 0% 1% (in € m) development driven by oral care and specialties ▪ Hydrogen peroxide stable on (weak) prior-year level Inorganics +19%
Slide 27: Infrastructure / Other
Infrastructure / Other Adj. EBITDA (in € m) Thereof: Infrastructure ▪ Oxeno (C4): still benefiting from higher +48% margins due to supply chain disruptions associated with Middle East conflict, but below very strong Q2 levels 100 80 ▪ Infrastructure: as usual high level of 54 stability an
Slide 28: Net financial debt development Q3 2026
Net financial debt development Q3 2026 3,620 3,292 562 43 40 42 193 June 30, 2026 F from C ash outflows C Net interest Addition / reduction Other September 30, 2026 Net financial operating for investments payments in leasing liabilities Net financial debt activi
Slide 29: Development of debt and leverage over time
Development of debt and leverage over time Total 3.0x 2.3x 2.4x 2.1x Leverage1 3,310 3,311 3,292 Net financial debt (€3,292 m) 3,253 Net financial ▪ Net financial debt slightly decreased debt ▪ Total leverage reduced to 2.1x, (in € m) supported by lower net financial debt and higher LTM
Slide 30: Segment overview by quarter
Segment overview by quarter Sales (in € m) Q1/25 Q2/25 Q3/25 Q4/25 FY 2025 Q1/26 Q2/26 Q3/26 Custom Solutions 1,427 1,367 1,340 1,358 5,492 1,334 1,422 1,394 Advanced Technologies 1,601 1,511 1,445 1,416 5,973 1,450 1,647 1,713 Infrastructure / Other1 749 621 606 628 2,604 643 824 718 Evonik Group 3
Slide 31: Upcoming IR events
Upcoming IR events Conferences & roadshows Upcoming reporting dates & events November 4, 2026 CFO Analyst Breakfast, London March 4, 2027 Q4/FY 2026 Reporting November 4, 2026 Roadshow, London (Jefferies) May 4, 2027 Q1 2027 Reporting November 5, 2026 Virtual Roadshow (Berenberg) June 3, 2027 Annual
Slide 32: Evonik Investor Relations Team
Evonik Investor Relations Team Christoph Finke Cédric Schupp Senior Vice President Investor Relations Director Investor Relations & ESG +49 174 9931647 +49 173 2552453 christoph.finke@evonik.com cedric.schupp@evonik.com Katharina Gayk Johanna Göbel Specialist Investor Relations Director Investor Rel
Slide 33: Disclaimer
Disclaimer In so far as forecasts or expectations are expressed in this presentation or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the oper
Slide 34: © evonik
© evonik